⌕
Agios Pharmaceuticals · AGIO · Nasdaq
Tenet 64 · Solid
Compare
$31.59−0.54%At closeTenet 64 · Solid
$31.59−0.17 (−0.54%)
At close: Nov 13, 2026, 4:00 PM ET· Nasdaq · USD

Agios Pharmaceuticals (AGIO) Stock

Agios Pharmaceuticals (AGIO) closed at $31.59 on Nov 13, 2026; its Tenet Score is 64 of 100 against 409 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

20 figures withheld by our checks. Each blank figure names its reason.

Key stats

Previous close
$31.59
Nov 13, 2026
Market cap
$1.9B
share price × the latest quarter's diluted weighted-average share count (vendor)
52-week range
22.24 – 46.00
low → high
Tenet Score
64/100
Solid · 409 Healthcare peers

Industry: Drugs · see every company filed here →

Agios Pharmaceuticals Inc scores 64/100. Solid. Strongest on financial health and value versus 409 Healthcare peers.

Tenet Score · vs sector

n=409
64/ 100
Solid
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
80
Quality
44
Health
82
Growth
49

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueBQualityDHealthBGrowthDMomentumF
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
1.9×
price to book value
P/S
13.4×
price to fiscal 2025 sales
ROE
−33%
return on equity
Operating margin
−873.9%
fiscal 2025, before interest and tax
Net margin
−264.8%
of revenue kept
Current ratio
9.69
current assets to liabilities
Net debt / EBITDA
—
Not meaningful: EBITDA is zero or negative.
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Agios Pharmaceuticals Inc

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a v…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=409) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 86 US ETFs · top wrappers by weightSee all ETFs holding AGIO →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

What sector and industry is Agios Pharmaceuticals in?

Agios Pharmaceuticals is in the Healthcare sector and the Drugs industry.

What is Agios Pharmaceuticals' Tenet Score?

Agios Pharmaceuticals' Tenet Score is 64 out of 100, ranked against 409 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.